Growing evidence places skeletal muscles’ impact on insulin resistance and systemic inflammation at the center of the NAFLD pathogenic cascade.
TORONTO (PRWEB) November 18, 2020
Recent studies highlight an important and independent relationship between sarcopenia and chronic liver diseases, particularly non-alcoholic fatty liver disease (NAFLD). While the impact of sarcopenia in patients with end-stage liver disease (ESLD) or decompensated cirrhosis is well established, emerging data underscores the importance of detecting sarcopenia in patients with early NAFLD.
Current muscle-based sarcopenia definitions fail to detect sarcopenia in the population with obesity, which is overrepresented in NAFLD. Until recently, the skeletal muscle-liver crosstalk and the impact of interventions on skeletal muscle have been largely overlooked in the research for NAFLD treatments. Growing evidence places skeletal muscles’ impact on insulin resistance and systemic inflammation at the center of the NAFLD pathogenic cascade.
In this webinar, experts in liver and metabolic diseases, as well as imaging, will review the latest research on how to assess and monitor sarcopenia in chronic liver disease. Research regarding how sarcopenia may impact chronic liver disease treatment, the current pathophysiological mechanisms linking skeletal muscle metabolism and sarcopenia to liver disease, as well as how these may be used to discover and develop new treatments will be explored. Finally, they will also discuss how rapid whole-body magnetic resonance imaging (MRI) has been utilized for quantitative, standardized and objective body composition assessments in recent sarcopenia research.
Join Manu Chakravarthy, MD, PhD, Executive Vice President of Clinical Development, Chief Medical Officer, Axcella Health Inc.; Mohammad Shadab Siddiqui, MD, Associate Professor of Medicine at Virginia Commonwealth University; and Mikael Forsgren, PhD, Senior Scientist, Liver Disease Lead Scientist, AMRA Medical Research, for a live webinar on Tuesday, December 8, 2020 at 11am EST (4pm GMT/UK).
For more information, or to register for this event, visit Muscle-Liver Crosstalk and Sarcopenia in Chronic Liver Disease: Novel Techniques and Clinical Evidence.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
